Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
OBT-076 by Oxford BioTherapeutics for Adenoid Cystic Carcinoma (ACC): Likelihood of Approval
OBT-076 is under clinical development by Oxford BioTherapeutics and currently in Phase I for Adenoid Cystic Carcinoma (ACC). According to...
Data Insights
OBT-076 by Oxford BioTherapeutics for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
OBT-076 is under clinical development by Oxford BioTherapeutics and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...